Zymeworks Inc.
ZYME
NASDAQ·Healthcare·Biotechnology·Mkt cap $2.2B
$29.71
▲ +1.00%
P/E
-14.71
Mkt Cap
$2.2B
52-Wk Range
$13.60–$30.62
52-Week Range
$13.60 - $30.62
P/E
Fwd P/E
Beta
Div Yield
Avg Vol
Shares Out
Mkt Cap
Price action
Price chart
Up 109.9% over the trailing year
Total returns
Price performance
Total return across standard periods - splits & dividends adjusted by FMP. Periods longer than 1Y show annualized in the tooltip.
Why we rate it this way
The thesis at a glance
Bull and bear case · plain-English context across the five lenses we evaluate.
Bull Case
4 reasons
- Proprietary bispecific antibody platform technology with demonstrated efficacy
- Strategic partnerships with major pharmaceutical companies providing validation and resources
- Multi-cancer indication pipeline addressing large addressable markets
- Experienced management team with oncology and biotherapeutic development expertise
Bear Case
1 risk
- Average volatility.
Growth
Turning profitable
Clinical trial progression and positive efficacy data for zanidatamab and ZW49
Value
Fairly valued vs Biotech & Therapeutics peers
Momentum
Strong
+19.9% over 3m
Quality
Excellent
Mixed fundamentals
Dividend
None
No dividend
Smart-money signal
Who's buying ZYME right now
Insider Form 4s, 13F institutional filings, and Congressional disclosures - at a glance.
Earnings track record
Recent earnings results
AI-summarized recap of last quarter, plus the surprise on every print.
Next: Nov 5, 2026
AUG 6, 2026
Reported EPS of -$0.62 vs -$0.56 consensus (-10.3% surprise). Revenue of $4.6M vs $4.5M expected (+1.1%).
EPS surprise · last 4Q
0 of 1 beats
Estimate
Actual
Q3 26
-10.3%
Revenue trend · last 8Q
—
+83%
+170%
+153%
+73%
-92%
-91%
-100%
Q3 24
Q4 24
Q1 25
Q2 25
Q3 25
Q4 25
Q1 26
Q2 26
$16.0M
$31.0M
$27.1M
$48.7M
$27.6M
$2.5M
$2.4M
$0
Margins · last 8Q
Gross
—
Operating
—
Profit
—
Wall Street consensus
5 analysts · 100% Buy
Live ratings and price targets aggregated across covering analysts.
Buy
100%
Hold
0%
Sell
0%
Median Price Target
$46.00
▲ +54.9% vs $29.71
Latest: HC Wainwright · Aug 26, 2026
1 analyst covering
vs Industry
How ZYME stacks vs Biotechnology
Stock metrics vs industry averages. Green = better than industry.
Industry comparison data unavailable for this stock.
Related